# OnCo record arqule (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/arqule/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "arqule" ;
  schema:name "ArQule"@en ;
  schema:alternateName "ArQule, Inc."@en ;
  schema:description "ArQule made pill-form drugs that block kinases, enzymes that drive cancer cell growth. Merck bought it in 2020, mainly for nemtabrutinib (then ARQ 531), a drug for blood cancers such as chronic lymphocytic leukaemia."@en ;
  schema:url <https://onco.cc/companies/arqule/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.merck.com/news/merck-to-acquire-arqule-advancing-leadership-in-oncology/>, <https://www.sec.gov/Archives/edgar/data/310158/000114036120000884/ex99_a5a.htm>, <https://atlasventure.com/portfolio/> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/richter-transformation-cll/>, <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/btk/> ;
  onco:drugs <https://onco.cc/drugs/nemtabrutinib/> ;
  onco:trials <https://onco.cc/trials/nct03162536/> .